Method Optimization for the Quantification of the NAD

Study Overview
=================
Brief Summary
-----------------
Method optimization for the quantification of the NAD metabolome in human whole blood, and evaluation of baseline inter and intra-subject variability.

Detailed Description
-----------------
Whole blood from healthy participants will be collected to optimize analytical method based on liquid chromatography tandem mass spectrometry (LC-MS/MS) for the analysis of the NAD metabolome in biological samples. Parameters such as collection volume and anti-coagulants will be investigated for optimal quantification. Moreover, inter- and intra-subject variability of NAD metabolite levels in whole blood will be evaluated. Plasma and urine will also collected for method development and variability measurements.

Official Title
-----------------
Method Optimization for the Quantification of the NAD (Nicotinamide Adenine Dinucleotide) Metabolome in Human Whole Blood, Plasma, and Urine, and Evaluation of Baseline Inter and Intra-subject Variability

Conditions
-----------------
NAD

Intervention / Treatment
-----------------
* Other: Laboratory method validation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy men and women (based on anamnesis), Age between 18 and 55 years, Body Mass Index (BMI) = weight (kg) / height (m)2 between 18.5 to 28 kg/m2. Exclusion Criteria: Pregnant or lactating women Sick or with a strong cold With vitamin B3 supplementations or under low carbohydrate of ketogenic diet Under prescribed chronic medication, except contraceptive pill.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Laboratory method validation|Test several sampling conditions|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of NAD metabolite concentrations in whole blood, collected with different tubes and anticoagulants. | NAD metabolites in whole blood will be quantified by liquid chromatography-tandem | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimation of inter- and intra-subject variabilities of NAD metabolites in whole blood | Descriptive estimates of the inter and intra subjects variances will be calculated with the standard formulas. | through study completion, an average of 1 year | 
| Validation of the method for a set of NAD metabolites in plasma and urine (including determination of Limit Of Detection-LOD, Limit Of Quantification- LOQ). | NAD metabolites in urine and in blood will be quantified to enable to measure several validation parameters, such as intra and interday precision, LOD, LOQ, r2. | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NAD quantification in blood and urine